
INC Research appoints Pfizer head
pharmafile | February 7, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | INC Research, Pfizer, setnik
Clinical research organisation INC Research has hired Dr Beatrice Setnik from Pfizer to be its vice president of Clinical Pharmacology.
Setnik will support the firm’s Early Phase business unit, providing scientific direction on matters related to abuse liability.
Setnik joins INC Research from Pfizer, most recently serving as a senior director there for its Medical Development-Neuroscience unit where she led clinical development.
Prior to Pfizer, she worked as a research scientist providing scientific input on speciality Phase I-II clinical trials, including abuse potential studies.
“We are delighted to welcome Beatrice to our clinical pharmacology team,” said Dr Pierre Geoffroy, vice president, Early Phase at INC Research.
“Dr Setnik’s extensive knowledge and experience in the area of human abuse liability assessment and risk evaluation, as well as in CNS drug development, clinical trial design and strategic lifecycle management, will be instrumental in furthering the development of our abuse potential capabilities and new scientific growth strategies for early phase clinical research.”
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …






